I-spy trials: quantum leap sponsors the i-spy trials (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis). I-spy has been re-engineering the approach to clinical trials, with a goal of getting the right drug to the right patient at the time when they will benefit most, and to achieve this faster than possible in previous trial models. Additionally, i-spy aims to significantly reduce the overall cost, time, and number of patients required to bring new drugs to market. The i-spy trial program integrates and links phase i (i-spy phase 1), phase II (i-spy 2), and future phases to build a pipeline of novel agents and accelerate the process of identifying the subset of high-risk breast cancer patients that will benefit from these new agents, and get these drug into the clinic in a timely manner.

Service Area:

No locations for this program